Commercialisation of Sienna’s telomerase biosensing technology (TBT) for cancer

The project will see the hiring of an experienced executive who will accelerate the development of Sienna’s novel telomerase technology for the diagnosis and monitoring of cancer (bladder cancer) and expand the technology for use in prostate cancer, while assisting in negotiating licensing agreements with global partners.